Follow us on Twitter
twitter icon@FreshPatents


Nonalcoholic Steatohepatitis patents

      

This page is updated frequently with new Nonalcoholic Steatohepatitis-related patent applications.




 Uses of mito-ob transgenic mice patent thumbnailUses of mito-ob transgenic mice
The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba


 Novel composition for nonalcoholic fatty liver disease (nafld) patent thumbnailNovel composition for nonalcoholic fatty liver disease (nafld)
The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited


 Glucagon and glp-1 co-agonist compounds patent thumbnailGlucagon and glp-1 co-agonist compounds
The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company


 Lysosomal acid lipase therapy for nafld and related diseases patent thumbnailLysosomal acid lipase therapy for nafld and related diseases
The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center


 Differential diagnosis of liver disease patent thumbnailDifferential diagnosis of liver disease
The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls.
The Regents Of The University Of California


 Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy patent thumbnailMethods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (nash).
Intekrin Therapeutics, Inc.


 Engineered polypeptides having enhanced duration of action and reduced immunogenicity patent thumbnailEngineered polypeptides having enhanced duration of action and reduced immunogenicity
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

 A novel composition for nonalcoholic fatty liver disease (nafld) patent thumbnailA novel composition for nonalcoholic fatty liver disease (nafld)
The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited


 Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis patent thumbnailChi3l1 for the detection and treatment of nonalcoholic steatohepatitis
Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease.
Yale University


 Engineered polypeptides having enhanced duration of action patent thumbnailEngineered polypeptides having enhanced duration of action
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.


Highly soluble leptins

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii).
Aegerion Pharmaceuticals, Inc.

Method of treating advanced non-alcoholic steatohepatitis

Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for inhibiting or treating advanced nonalcoholic steatohepatitis, conditions leading to or arising from it, and/or negative effects of each thereof.. .

Novel biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kda protein fragment consisting of amino acid sequence expressed by sequence no.
Mcbi, Inc.

Anti-angptl3 antibodies and uses thereof

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth.
Regeneron Pharmaceuticals, Inc.

Methods for the treatment of nonalcoholic steatohepatitis

The present invention relates to the treatment of nonalcoholic steatohepatitis (nash), in particular to a compound that inhibits mir-21 expression for use in the treatment of nonalcoholic steatohepatitis.. .
Universite Paris Descartes

Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.

Compounds for control of appetite

This invention relates generally to neuropeptide y (“npy”) y4 receptor agonists including pancreatic polypeptide (pp), analogs thereof, and peptide fragments of pp, e.g. Pp(32-36), and analogs thereof, to pharmaceutical compositions containing such y4 receptor agonists, and to methods for treatment of mammals using the same.

Engineered poypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.

Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis

In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .



Nonalcoholic Steatohepatitis topics:
  • Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Fatty Liver
  • Alcoholic Fatty Liver
  • Liver Disease
  • Hyperlipidemia
  • Dyslipidemia
  • Hepatitis A
  • Liver Fibrosis
  • Metabolic Syndrome
  • Syndrome X
  • Metabolic Syndrome X
  • Polypeptide
  • Overweight
  • C Syndrome


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Nonalcoholic Steatohepatitis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nonalcoholic Steatohepatitis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2172

    file did exist - file did put1277

    3 - 1 - 20